Martin Illemann

Martin Illemann is a seasoned medical advisor with extensive experience in oncology and haematology, currently serving as the Nordic Medical Advisor at Sanofi since June 2022, focusing on multiple myeloma and market access. Prior roles include Medical Advisor positions at Janssen Pharmaceutical Companies, specializing in CLL and B-cell malignancies, and Pfizer, managing portfolios in various haematological cancers. Martin's background also includes significant research experience, having held positions as a Sr. Pathology Research Scientist at Gubra, project leader and postdoc at Finsen Laboratory, and a postdoc at McGill University, where leadership and project management were key responsibilities. Educationally, Martin holds a PhD in Biological and Biomedical Studies from the University of Copenhagen and a Civilingeniør degree in Chemistry from the Technical University of Denmark.